Innovative science

We have applied our scientific insights into the structure, biology and function of individual isoforms of PI3K and HDAC enzymes to de novo-design and develop innovative new medicines with significant clinical potential in the treatment of cancer. Karus’s first drug candidate, KA2237, is in early patient trials at the MD Anderson Cancer Center in Houston.

Read more »

Clinical pipeline

We are collaborating with The University of Texas MD Anderson Center, the world’s leading cancer research and care center, for the pre-clinical and clinical development of our compounds.

KA2237 – Early clinical

KA2237 is a potent, dual-selective inhibitor of phosphoinositide 3-kinase (PI3K)-p110β and p110δ that has a combined targeted and immunotherapeutic mode of action - inhibiting oncogenic pathways within the cancer cell, and driving immunotherapeutic activity within the tumor microenvironment.

Read more »

KA2507 – Late pre-clinical

KA2507 is a highly-potent and selective inhibitor of HDAC6. Selective HDAC6 inhibition promotes tumor cell apoptosis through the suppression of aggresome formation. In addition, KA2507 drives immunotherapeutic tumor cell growth inhibition by modulating key tumor microenvironment markers, including downregulation of PD-L1.

Read more »

Latest News

  • 21 October 2016
    Karus Therapeutics presenting at BIO-Europe
    Read more »
  • 05 October 2016
    Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center
    Read more »
  • 03 October 2016
    Karus Therapeutics giving lecture at BIO Investor
    Read more »
  • 07 September 2016
    Karus Therapeutics giving lecture at 10th Annual Symposium – Next Generation Histone Deacetylase Inhibitors
    Read more »
  • 01 September 2016
    Karus Therapeutics delivering lecture at 9th Annual Kinase Inhibitor Discovery conference
    Read more »
  • 21 April 2016
    Karus Therapeutics presenting at BioEquity 2016
    Read more »